PMID- 32564759
OWN - NLM
STAT- MEDLINE
DCOM- 20210805
LR  - 20210805
IS  - 2212-3911 (Electronic)
IS  - 1574-8863 (Linking)
VI  - 15
IP  - 3
DP  - 2020
TI  - A Prospective Analysis of Potential and Observed Drug-Drug Interactions, Adverse 
      Events and its Associated Risk Factors in Hospitalized Cardiology Patients in 
      Benin.
PG  - 190-197
LID - 10.2174/1574886315666200621184913 [doi]
AB  - BACKGROUND & AIMS: The objective is to ascertain the pattern of potential 
      drug-drug interactions (pDDIs) and record any observed DDIs and adverse events 
      (AEs) in hospitalized Beninese cardiology patients from Sub-Saharan Africa and 
      analyze all risk factors associated with DDIs and AEs. METHODS: It was a 
      prospective study in which data including AEs were assessed from medical files 
      and interview of patients and their relatives. Patients who were treated with 
      more than two drugs and who remained in the hospital for at least 48 hours were 
      included. A computerized database system Pharma IAM- VIDAL version 2011 was used 
      to identify the pattern for potential DDIs. RESULTS: 156 patients were included 
      in this study. The prevalence of potential DDIs was estimated at 93 % (145/156). 
      Forty (5.1%) among 804 potential DDIs identified were observed clinically. The 
      observed DDIs were attributable to low blood pressure (27.5%), hyponatremia 
      (22.5%), hemorrhage (20.0%), hyperkalemia (17.5%) and nephrotoxicity (7.5%). The 
      combination of spironolactone and furosemide resulted in hyponatremia while the 
      combination of enoxaparin and potassium resulted in hyperkalemia. ACE inhibitor 
      (or ARAII) in combination with furosemide resulted in the nephrotoxicity cases 
      observed. Enoxaparin, Acetyl salicylic acid, Acenocoumarol and Clopidogrel were 
      decreasingly involved in the pairs of drugs responsible for observed hemorrhages. 
      29 patients out of 156 (18.6%) had at least one AE. AEs were mainly (34.2%) of 
      metabolic type. Severe AEs, which represented 18.4% was mostly from 
      nephrotoxicity and metabolic disorders. More than 14 active substances multiplied 
      the risk factor for AEs occurrence by 42, while more than 14 days hospitalization 
      increased this risk by 42. CONCLUSION: This study highlights the need to optimize 
      treatments by strictly regulating blood pressure, serum sodium and potassium 
      levels, coagulation parameters and looking for clinical signs of hemorrhage. 
      Physician should be aware of certain drug associations that may carry a risk of 
      severe adverse events.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Allabi, Aurel C E
AU  - Allabi ACE
AD  - Pharmacology Department, Faculty of Health Sciences, University of Abomey- 
      Calavi, 01 BP 188Cotonou, Benin.
FAU - Tchabi, Yessoufou
AU  - Tchabi Y
AD  - Cardiology Department of Teaching Hospital CNHU-HKM, Faculty of Health Sciences, 
      University of Abomey- Calavi, 01 BP 188 Cotonou, Benin.
FAU - Hounkponou, Murielle
AU  - Hounkponou M
AD  - Cardiology Department of Teaching Hospital CNHU-HKM, Faculty of Health Sciences, 
      University of Abomey- Calavi, 01 BP 188 Cotonou, Benin.
FAU - Quenum, Rebecca
AU  - Quenum R
AD  - Pharmacology Department, Faculty of Health Sciences, University of Abomey- 
      Calavi, 01 BP 188Cotonou, Benin.
FAU - Vehounkpe-Sacca, Jeanne
AU  - Vehounkpe-Sacca J
AD  - Cardiology Department of Teaching Hospital CNHU-HKM, Faculty of Health Sciences, 
      University of Abomey- Calavi, 01 BP 188 Cotonou, Benin.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - United Arab Emirates
TA  - Curr Drug Saf
JT  - Current drug safety
JID - 101270895
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Benin
MH  - Cardiovascular Diseases/*physiopathology
MH  - *Drug Interactions
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology
MH  - Female
MH  - *Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Prospective Studies
MH  - Risk Factors
MH  - Young Adult
OTO - NOTNLM
OT  - Benin
OT  - Drug-drug interaction
OT  - West Africa
OT  - adverse event
OT  - cardiology
OT  - hospitalized
EDAT- 2020/06/23 06:00
MHDA- 2021/08/06 06:00
CRDT- 2020/06/23 06:00
PHST- 2019/11/23 00:00 [received]
PHST- 2020/04/08 00:00 [revised]
PHST- 2020/05/15 00:00 [accepted]
PHST- 2020/06/23 06:00 [pubmed]
PHST- 2021/08/06 06:00 [medline]
PHST- 2020/06/23 06:00 [entrez]
AID - CDS-EPUB-107526 [pii]
AID - 10.2174/1574886315666200621184913 [doi]
PST - ppublish
SO  - Curr Drug Saf. 2020;15(3):190-197. doi: 10.2174/1574886315666200621184913.